UNSPSC 51383002: Nimazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H9ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N71M372MP4, chemically known as 1-imidazolidineacetonitrile, 3-(p-chlorophenyl)-4-imino-2-oxo- but generally known as nimazone, which bears US NIH Compound Identifier 28418. European Medicines Agency schedules Nimazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09293MIG. The term NIMAZONE is an International Non-Proprietary Name.

UNSPSC 51383002 Nimazone is a Commodity code under which state and local governments procure naloxone (opioid antagonist medication) and related drug deactivation or safe disposal systems to support public health and emergency response initiatives. Recent opportunities show jurisdictions buying naloxone in bulk for community health programs, medical responders, and opioid overdose intervention — quantities ranging from hundreds to thousands of units annually, with quarterly or as-needed delivery schedules to designated health facilities or distribution centers. The code also captures pharmaceutical procurement more broadly, including generic multi-source drugs and over-the-counter products supplied through state and local cooperative purchasing frameworks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work spans competitive sealed bidding for naloxone and drug deactivation systems, exploratory market RFIs for direct-to-manufacturer pharmacy programs, and framework RFPs for generic pharmaceutical supply across multiple state jurisdictions.

Recent activity clusters in Florida, Texas, and Minnesota. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the procurement includes FEMA potential funding and standard compliance requirements (E-Verify, workers' compensation, commercial general liability insurance). The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and wholesaler channels, signaling state interest in alternative pharmaceutical supply models. MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multiple manufacturer contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and pricing evaluation weighted 75 percent on competitiveness; vendors must meet cGMP and Drug Supply Chain Security Act compliance, maintain $5 million commercial general liability coverage, and accept a 3 percent administrative fee on all purchases.